February 9, 2023 09:38 AM ESTUpdated 05:48 PM
Deals
Bioregnum

The top 100 ven­ture in­vestors in bio­phar­ma to­day. Who's stay­ing at the deals ta­ble?

Re­mem­ber how good 2020 was for biotech ven­ture num­bers? Now hold that thought.

Div­ing in­to the num­bers for life sci­ence ven­ture in­vestors last year, Deal­For­ma …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times